Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > CEPH > Summary

Cephalon Inc.
(CEPH)

65.78USD   Up0.78 (1.20%)   
At 2:30AM IST
 Cephalon Inc. (NasdaqNM:CEPH) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 65.78USD
Trade Time:2:30AM IST
Change:Up0.78 (1.20%)
Prev Close:65.00
Open:65.29
Bid:65.27 x 300
Ask:66.34 x 200
1y Target Est:72.27
Day's Range:64.64 - 66.50
52wk Range:52.55 - 79.68
Volume:1,669,476
Avg Vol (3m):2,062,190
Market Cap:4.91B
P/E (ttm):18.18
EPS (ttm):3.62
Div & Yield:N/A (N/A%)
Add CEPH to Portfolio   Download Data

HEADLINES

 
•Biotech Deal-Making Crosses Borders as Capital Markets Slide - Seeking Alpha  - Tue 3:02PM
•Cell Therapeutics’ Last Hope for Survival, Dashed - Minyanville.com  - Tue 12:50AM
•12 S&P 500 Stocks with Attractive Valuations - Seeking Alpha  - Mon, Feb 8
•Lower Q3 Loss for Alkermes - Zacks.com  - Fri, Feb 5
•Alkermes reports 3Q loss, smaller than expected - AP  - Fri, Feb 5
•CEPHALON INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - EDGAR Online  - Fri, Feb 5
•Clinical trial services company BioClinica wins contract with Cephalon - bizjournals.com  - Thu, Feb 4
•4 Companies Experiencing Speculative Option Activity - Seeking Alpha  - Wed, Feb 3
•[$$] Trader Prepares for VIX to Drop Back Below 20 - The Wall Street Journal Online  - Wed, Feb 3
•Latin America Led World Stock Funds Lower In January - Investor's Business Daily  - Wed, Feb 3
•Cephalon Bullish Play - Forbes.com  - Wed, Feb 3
•CEPHALON INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officer - EDGAR Online  - Wed, Feb 3
•Cephalon: Long-Term Support Starting to Line Up - Seeking Alpha  - Wed, Feb 3
•Cephalon Enters Generics Market - Zacks.com  - Tue, Feb 2
•Professional Investors Like Healthcare Stocks - Seeking Alpha  - Tue, Feb 2
» More Headlines for CEPH...

ANALYST

 
EPS Est (next year) (Dec-09) :5.94
EPS Est (in 2 years) (Dec-10) :6.24
Avg Rec (current)*:2.2
PEG Ratio:0.97
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.

» Full Company Profile